What We have Learned about Pain from Rodent Models of Arthritis?

被引:0
作者
Inglis, Julia J. [1 ,2 ]
Schutze, Mark U. [3 ]
McNamee, Kay E. [4 ]
机构
[1] Murdoch Univ, Sch Vet & Biomed Sci, Perth, WA, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Pain Management, Perth, WA, Australia
[4] Imperial Coll London, London W6 8LH, England
关键词
Pain mechanisms; animal models; rodent; osteoarthritis; rheumatoid arthritis; analgesics;
D O I
10.2174/157339710791792748
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis (RA) and Osteoarthritis (OA) are both common diseases of the joints. RA is distinguished by inflammation and synovitis leading to joint destruction, whereas OA is typified by degenerative and mostly noninflammatory disease. Although differing in their pathology, both forms can elicit chronic disabling pain in patients. Relief from this pain is an unmet need for many patients, and this has lead to a drive to understand the pain mechanisms occurring in each disease in order to develop new analgesics. This necessitates the use of pre-clinical models. Here we discuss the methods and limitations of animal pain assessment, rodent models of RA and OA, and how these models have been used to investigate the genesis of pain. Specifically, we focus on processes studied in both RA and OA models, and how the mediators involved in the development of pain may differ between these two arthritic states and during acute and chronic pain. From this we have learnt that the key mediators of RA pain include inflammatory cells, inflammatory cytokines, astrocytes, substance P, and CGRP. Endogenous analgesic mediators in RA include beta-endorphin, mu-opioid receptor, and various anti-inflammatory cytokines. Less is known of the mediators of OA pain, but important factors include CGRP, TRPV1, NGF, VIP and the mu-opioid receptor. Interestingly, several factors have been found not to play a role in OA pain, including glial cells, neutrophils and TNF. It must be noted that the vast majority of candidate drugs from animal research never reach the human clinic, in part due to false positives from animal models. This may be due to flaws in the models themselves, the methods used to assess pain, the physical properties of the candidate drug, or an inherent difference between animal and human pain pathways. By developing more clinically relevant models, novel diseasespecific analgesics are being developed with the hope of improving the quality of life for sufferers of arthritis pain.
引用
收藏
页码:194 / 207
页数:14
相关论文
共 50 条
  • [41] Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics
    Laura Padrón-Barthe
    Fernando Domínguez
    Pablo Garcia-Pavia
    Enrique Lara-Pezzi
    Basic Research in Cardiology, 2017, 112
  • [42] Intra-articular Corticosteroids for Knee Pain-What Have We Learned from the Equine Athlete and Current Best Practice
    Mcllwraith, C. Wayne
    Lattermann, Christian
    JOURNAL OF KNEE SURGERY, 2019, 32 (01) : 9 - 25
  • [43] Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics
    Padron-Barthe, Laura
    Dominguez, Fernando
    Garcia-Pavia, Pablo
    Lara-Pezzi, Enrique
    BASIC RESEARCH IN CARDIOLOGY, 2017, 112 (05)
  • [44] Aging and neurogenesis in the adult forebrain: what we have learned and where we should go from here
    Hamilton, Laura K.
    Joppe, Sandra E.
    Cochard, Loic M.
    Fernandes, Karl J. L.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2013, 37 (12) : 1978 - 1986
  • [45] 30 Years of Biotherapeutics Development-What Have We Learned?
    Ghilardi, Nico
    Pappu, Rajita
    Arron, Joseph R.
    Chan, Andrew C.
    ANNUAL REVIEW OF IMMUNOLOGY, VOL 38, 2020, 38 : 249 - 287
  • [46] Rodent models of postherpetic neuralgia: How far have we reached?
    Ou, Mingxi
    Chen, Jiamin
    Yang, Shaomin
    Xiao, Lizu
    Xiong, Donglin
    Wu, Songbin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Vascular Calcification in Chronic Renal Failure What Have We Learned From Animal Studies?
    Neven, Ellen
    D'Haese, Patrick C.
    CIRCULATION RESEARCH, 2011, 108 (02) : 249 - 264
  • [48] Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned
    Sofat, Nidhi
    Beith, Iain
    Anilkumar, P. G.
    Mitchell, Philip
    REVIEWS ON RECENT CLINICAL TRIALS, 2011, 6 (02) : 114 - 126
  • [49] Molecular transport in articular cartilage - what have we learned from the past 50 years?
    DiDomenico, Chris D.
    Lintz, Marianne
    Bonassar, Lawrence J.
    NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (07) : 393 - 403
  • [50] Cell-specific ablation in the testis: what have we learned?
    Smith, L. B.
    O'Shaughnessy, P. J.
    Rebourcet, D.
    ANDROLOGY, 2015, 3 (06) : 1035 - 1049